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Purpose: To determine the hemostatic response after acute aerobic exercise in Obstructive 
Sleep Apnea (OSA). Methods: Eighteen males were recruited from the university and local 
community. Individuals who presented evidence of cardiovascular, pulmonary, or 
metabolic disease were excluded. Apnea-Hypopnea Index (AHI) > 5 was criteria for OSA. 
Subjects performed a treadmill exercise test at 35% and 70% predicted VO2reserve during 
the morning hours. Pre exercise blood samples were obtained after 15 minutes supine rest 
and within two minutes following exercise. Repeated Measures ANOVA were performed 
for Factor VIII antigen, tPA antigen, tPA activity, and PAI-1 activity across two time points 
(Pre vs. Post) and between conditions (OSA vs. Controls). Correlational analysis compared 
all hemostatic factors with age, BMI, and AHI. Results: Mean AHI was (13.00 + 12.6) 
indicating mild OSA severity. There were no exercise x condition interaction for any 
observed hemostatic markers (P > 0.05). There was a significant main effect for exercise 
in Factor VIII, tPA antigen, and tPA activity in both groups (P < 0.05). There was no main 
effect for OSA except an observed trend in PAI-1 which remained elevated after exercise 
(P = 0.05). FVIII:Ag and BMI (R = .520), tPA:Ag and AHI (R = .489), and tPA:Ag and 
age (R = .496) were positively correlated (P < 0.05). Conclusion: The hemostatic response 
after acute aerobic exercise is unaffected in mild OSA although PAI-1 activity seems to be 
elevated impacting fibrinolytic potential. BMI seems to correlate with FVIII:Ag, while 
AHI and age correlate with tPA:Ag.  
 







Obstructive Sleep Apnea (OSA) is highly prevalent across populations and appears 
to affect approximately 2 - 4 % of the middle aged adults (38).  An estimated 85% of 
individuals with clinically significant OSA are undiagnosed with a large impact on males 
(28, 51). OSA is characterized by repetitive interruptions of ventilation during sleep due to 
a complete cessation of airflow or a significant decrease in airflow with a concurrent 
decrease in oxygen saturation (53). Patients with OSA exhibit reductions in the size of the 
pharyngeal airway directly due to obesity; and/or other obstacles including bone and soft 
tissues (38, 61). Children may also be affected by this condition due to tonsils and adenoids 
(53). During wakefulness, greater activation of the pharyngeal dilator muscles results in a 
patent airway that is less likely to collapse (36). However, during sleep, activation is 
reduced to the upper airway dilator muscles promoting collapse and consequent arousal 
(36). Increasing arousal during sleep contributes to excessive daytime sleepiness that could 
lead to other negative outcomes (53).  
OSA has been associated with numerous health conditions and several risk factors 
may predispose individuals to develop the condition. Risk factors include genetic factors 
that affect the craniofacial anatomy (35), age, sex, obesity (45), pregnancy, diabetes, and 
hypothyroidism (52). Many environmental factors also influence this risk such as smoking 
and alcohol use (45). OSA is a risk factor itself for the development of other diseases such 
as hypertension, heart failure, arrhythmias, CAD, and stroke (28). Signs of OSA include 
disturbed sleep (snoring and restlessness), daytime fatigue, and irregular breathing patterns 





The diagnosis of OSA is most commonly determined using a multi-channel 
analysis (polysomnography) utilizing an EEG, EOG, ECG, and oximetry along with an 
extensive physical and medical history examination (8). The readily accepted diagnosis for 
the disorder is defined as five or more apnea-hypopneas per hour of sleep (> 5 AHI) 
(43,38,8). Apnea is defined as a complete cessation of airflow greater than or equal to ten 
seconds (> 10 s) while hypopnea is a decrease in airflow of at least 50 %, lasting at least 
ten seconds (> 10 s), and accompanied by at least a 4 % decrease in oxygen saturation (8). 
Although discrepancies with the definition of a hypopnea and the concomitant decrease in 
oxygen saturation exist, a reduction of at least 4 % shows the greatest association with 
cardiovascular disease compared to higher saturations (44).   
It has been well established that the presence of OSA is associated with a greater 
incidence of cardiovascular disease (CVD), which increases with disease severity (40, 50, 
30, 63, 55, 41,). Marshall et al. reported moderate to severe OSA to be independently 
associated with increased risk of all-cause mortality, stroke and cancer after a 20 year 
follow-up (30). Results also show that efficient treatment of OSA has a beneficial impact 
on the disease and the subsequent CVD risk (29, 64). Similarly, Marin et al. reported the 
odds ratio of fatal or non-fatal cardiovascular events with patients under CPAP treatment 
were not significantly different than simple snorers and mild-moderate untreated persons 
(29). Previous studies have shown that sleep disordered breathing (SDB) contributes to the 
initial progression of atherosclerosis, suggesting OSA may be an independent risk factor 
for CVD incidence (5, 16, 19). In particular, Fox et al. found that increasing OSA severity 





CVD or common risk factors compared to matched controls (19). Therefore, OSA may 
have a mechanistic role in the progression of cardiovascular disease.  
Hemostasis is balanced by two mechanisms: coagulation, otherwise known as 
blood clotting, and fibrinolysis, the dissolution of a blood clot. Coagulation incorporates 
two pathways of activation that eventually result in the formation of thrombin and blood 
clot. Shortly after the Second World War, Davie and Ratnoff discovered a ‘waterfall’ like 
sequence of enzymes acting as substrates to other activated enzymes that lead to the 
formation of a stable fibrin clot (15). This proposed sequence is independent of factors 
extrinsic to the blood and is known as the intrinsic pathway. The intrinsic pathway is 
initiated by the activation of Factor XII which sequentially activates Factor XI which 
further activates Factor IX. In the presence of Factor VIII, Factor IX then activates Factor 
X which forms a complex with prothrombin generating thrombin (37). The extrinsic 
pathway is initiated through a subendothelial derived enzyme, Tissue Factor. In the event 
of vessel damage, Tissue Factor reacts in the presence of Factor V which further activates 
the reaction of Factor X and prothrombin (37). The common pathway has been described 
as the pathway where the intrinsic and extrinsic pathways overlap. The activation of Factor 
X and the subsequent generation of thrombin compose much of the common pathway 
(Figure 1). Thrombin is a key enzyme that contributes to platelet activation, fibrinogen 
conversion to fibrin, and amplification (12, 14). Thrombin also causes a feedback loop and 
activation of Factor XIII which stabilizes the unstable fibrin creating a firm meshwork of 
fibrin that will compose of much of the clot (37).  
Fibrinolysis consists of degradation of fibrin by a serine protease, plasmin. 





plasmin. This most important known activators are tissue-type plasminogen activator (t-
PA) and urokinase plasminogen activator (uPA) produced by the endothelium (7). uPA has 
a lower affinity for plasminogen and therefore much of the process of plasmin formation 
is performed by tPA (9). These activators have particularly short half-lives (approximately 
4 – 8 minutes) as they are either cleared by the liver or inactivated by inhibitors (9). The 
most common of these inhibitors are Plasminogen Activator Inhibitor-1 (PAI-1), 
Plasminogen Activator Inhibitor-2 (PAI-2), and α2-antiplasmin (54). The functional 
balance between coagulation and fibrinolysis is of the upmost importance so the circulation 
can remain in a closed circuit without either excessive clotting or bleeding.  
Much of the clinical evidence suggests greater coagulation potential and lower 
fibrinolytic activity in individuals with CVD (23, 20, 31). Folsom et al. found that markers 
of coagulation potential, Factor VIII and von Willebrand Factor (vWF), are associated with 
cardiovascular disease in both men and women (18). Specifically, increased FVIII and 
vWF have also been associated with higher incidence of ischemic heart disease and 
endothelial dysfunction (23, 18, 32, 49, 57). Further, Tracy et al. indicated that Factor VIII 
was significantly associated with coronary heart disease (CHD) and mortality in men and 
stroke/transient ischemic attacks in women (57). In the Northwick Park Heart Study, 
researchers found decreased fibrinolytic activity to be the main determinant of ischemic 
heart disease in younger men (31). Thogersen et al. showed that elevated plasma levels of 
PAI-1 and tPA antigen were associated with a first acute myocardial infarction for men 
and women (56). These studies indicate the clinical importance of hemostatic variables and 





Individuals with OSA exhibit an altered hemostatic balance. Guardiola et al. 
observed decreased whole blood clotting time in individuals with untreated OSA both 
before sleep and upon waking (22). The hypoxic environment associated with OSA may 
explain this prothrombotic state (60). Furthermore, it appears the prothrombotic state is 
due to a decrease in fibrinolytic activity rather than an increase in coagulation factors (6, 
47). However, evidence also suggests that hypoxic conditions result in a shortened 
coagulation time with a concurrent rise in Factor VIII (6). PAI-1 is positively associated 
with AHI, and oxygen saturation (SpO2) suggesting disease severity contributes to reduced 
fibrinolytic activity (59, 60, 65). Von Kanel et al. reported a higher AHI and increased time 
spent below 90 % SpO2 were associated with higher PAI-1 levels in relatively healthy 
populations (60). A possible mechanism for this relationship is the up regulation of PAI-1 
transcription with concomitant increases in PAI-1 mRNA stability during hypoxia, which 
is exacerbated by low tPA expression (42).  
 Many instances of myocardial infarction are preceded by physical exertion (21,34). 
Acil et al. found that persons with coronary artery disease exhibit a hemostatic balance 
favoring greater coagulation after an acute bout of exercise (1). This could be 
mechanistically linked with exertion-related ischemic events as occlusive thrombi are 
responsible for a greater portion of exertion –related events than events triggered by other 
causes (21). Myocardial infarctions seem to occur more frequently in sedentary individuals 
after physical exertion, particularly when the activity is strenuous (21, 34). During exercise, 
both coagulation and fibrinolysis increase proportional to intensity (33). Early research 
showed an elevation in coagulation potential during exercise, particularly due to an 





in Factor VIII is partially explained through beta-adrenergic-receptor stimulation (11).  
There is also a concomitant increase in fibrinolysis, due to increases in tPA and decreases 
in PAI-1 (26, 11, 3, 17, 4, 24, 48, 27, 43, 61, 13, 62) which change in proportion to the 
intensity of exercise (24, 48, 62). Following exercise, there is evidence for a prothrombotic 
state as markers of coagulation potential remain elevated for an hour into the post-exercise 
period (39), while a significant decrease in fibrinolytic potential occurs within 10 minutes 
(13, 39).   
 Although hemostatic responses to exercise are clinically important, these responses 
are relatively unknown in obstructive sleep apnea patients. Rangemark et al. found that 
OSA subjects exhibited increases in PAI-1 activity with values remaining significantly 
elevated before and after 4 minutes of submaximal cycle ergometer exercise compared to 
matched controls (46). After exercise, tPA showed a four-fold increase but did not 
significantly differ between groups (46). However, this study did not analyze any factors 
of coagulation other than platelet activity, which did not significantly change (46). The aim 
of this study is to determine if acute aerobic exercise increases Factor VIII, tPA antigen 















 All subjects gave informed written consent on the study protocol approved by the 
James Madison University Institutional Review Board. OSA subjects were recruited from 
the JMU community and Sentara Rockingham Memorial Hospital (SRMH) Sleep Clinic. 
All SRMH subjects were diagnosed with sleep apnea and not currently using continuous 
positive airway pressure (CPAP) as treatment.  Eighteen males (> 18 years of age) with 
observed sleep problems or significant snoring were recruited for the present study. 
Mobility issues, and/or evidence of cardiovascular, pulmonary, and metabolic diseases were 
criteria for exclusion in both OSA and Non-OSA groups. Demographic data is presented in 
Table 1 for OSA and Normal individuals.   
To establish likelihood of Sleep Apnea and screen for exclusion criteria in 
community-recruited participants, administration of established sleep surveys including 
Berlin Questionnaire, Epworth Sleepiness Scale, IPAQ, STOP Questionnaire, a Pre-
Screening form, and Medical/Health History were completed prior to participation. 
Participants deemed ACSM High risk for cardiovascular disease (2), highly active 
lifestyles, and use of heart rate/blood pressure/ blood thinning medications were criteria 
for exclusion. Subjects were required to wear an ApneaLink (ResMed; San Diego, CA) 
device to measure sleep disturbances by thoracic measurements, oxygen saturation (SpO2), 
respiratory effort, and airflow during sleep hours.  The Apnea-Hypopnea Index (AHI) was 
used to determine the likelihood for OSA in these subjects. Apneas were defined as a 





defined as a decrease in ventilation of at least 50 % with a concomitant reduction of oxygen 
saturation. An AHI  > 5 is the accepted criteria for diagnosed OSA (53). Subjects recruited 
at SRMH Sleep Clinic were evaluated for any known diseases and exclusions which were 
reported to the researcher by the on-site physician. All data was collected in the Human 
Performance Lab of James Madison University. All written, electronic data and subject 
information was stored in a locked file cabinet and password locked laptop in a locked file 
cabinet and room within the laboratory. Each participant entering the study completed the 
appropriate questionnaires and visited the laboratory three non-consecutive days over the 
span of approximately 7 – 10 days.  
 
Treadmill Test 
 Testing was done in the morning following an overnight fast. A resting blood draw 
was administered after 15 minutes of supine rest. Prior to testing, a warm up of 3 to 4 
minutes was performed, after which subjects performed two, five minute stages of exercise 
at 35% and 70% estimated VO2 reserve. During the test, walking speed and incline level 
were adjusted to obtain desired intensity, respectively. Metabolic variables were monitored 
continuously using a metabolic measurement system (Parvo Medics; Sandy, UT). Heart 
rate was determined continuously via a Polar® heart rate monitor. Immediately following 
exercise, a second blood draw was obtained within two minutes of completing the exercise 
test. 
 





   Blood draws were obtained from an antecubital vein after 15 minutes of supine rest 
and within two minutes post exercise. Blood was collected in vacutainer tubes containing 
heparin, sodium citrate, and acidified citrate. Blood collected in heparin vials was 
immediately analyzed for hematocrit using the micro-hematocrit method. Samples 
collected in sodium citrate and acidified citrate were spun for 20 minutes at 15000 rpm in 
a refrigerated centrifuge. Plasma was extracted from spun samples and stored at -80⁰ C 
until analysis. Blood analysis was performed by standardized Enzyme-Linked 
Immunosorbent Assay (ELISA) for Factor VIII activity, tPA antigen, tPA activity, and 
PAI-1 activity. Post exercise values for all of these variables were corrected for plasma 
volume changes using the method described by Van Beaumont et al. (58). 
 
Statistical Analysis 
Factor VIII, tPA antigen and activity, and PAI-1 and activity is analyzed using 
Repeated Measures Analysis of Variance (ANOVA). OSA and Non-OSA individuals will 
be compared using time as a within- subject factor and presence of disease as a between 
subject factor from all samples. Post hoc testing was done using paired and independent t-
test with a Bonferroni correction factor. Correlation analysis was performed between all 
hemostatic variables and age, BMI, and disease severity. A priori statistical significance 
was set at P < 0.05. TPA antigen and PAI-1 activity were not normally distributed 
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Purpose: To determine the hemostatic response after acute aerobic exercise in Obstructive 
Sleep Apnea (OSA). Methods: Eighteen males were recruited from the university and local 
community. Individuals who presented evidence of cardiovascular, pulmonary, or 
metabolic disease were excluded. Apnea-Hypopnea Index (AHI) > 5 was criteria for OSA. 
Subjects performed a treadmill exercise test at 35% and 70% predicted VO2reserve during 
the morning hours. Pre exercise blood samples were obtained after 15 minutes supine rest 
and within two minutes following exercise. Repeated Measures ANOVA were performed 
for Factor VIII antigen, tPA antigen, tPA activity, and PAI-1 activity across two time points 
(Pre vs. Post) and between conditions (OSA vs. Controls). Correlational analysis compared 
all hemostatic factors with age, BMI, and AHI. Results: Mean AHI was (13.00 + 12.6) 
indicating mild OSA severity. There were no exercise x condition interaction for any 
observed hemostatic markers (P > 0.05). There was a significant main effect for exercise 
in Factor VIII, tPA antigen, and tPA activity in both groups (P < 0.05). There was no main 
effect for OSA except an observed trend in PAI-1 which remained elevated after exercise 
(P = 0.05). FVIII:Ag and BMI (R = .520), tPA:Ag and AHI (R = .489), and tPA:Ag and 
age (R = .496) were positively correlated (P < 0.05). Conclusion: The hemostatic response 
after acute aerobic exercise is unaffected in mild OSA although PAI-1 activity seems to be 
elevated impacting fibrinolytic potential. BMI seems to correlate with FVIII:Ag, while 
AHI and age correlate with tPA:Ag.  
 





 OSA is characterized by continuous episodes of arousal during sleep due to complete 
or partial cessation of airflow from pharyngeal collapse (30, 36, 22) and affects 2 – 4% of 
the middle-aged population (22). Studies have determined that mortality risk, with fatal and 
non-fatal events (i.e. traffic accidents), directly increases with AHI severity in sleep 
disordered breathing (40, 16). Observational studies show a possible causal relationship 
between OSA and atherosclerosis (4, 8, 10). One such study reported that middle-aged 
participants without diagnosed cardiovascular disease portrayed early indications of 
atherosclerosis (8). Therefore, OSA may have a mechanistic role in the progression of 
cardiovascular disease. 
 Much evidence suggests that an increase in blood coagulation, accompanied with 
decreased fibrinolysis, is associated with an increased risk for cardiovascular disease. The 
ARIC study found that markers of coagulation potential, Factor VIII and von Willebrand 
Factor (vWF), are associated with cardiovascular disease in both men and women (9). 
Similarly, the Cardiovascular Heart Study showed Factor VIII is independently associated 
with stroke/transient ischemic attacks and coronary heart disease (32). In the Northwick 
Park Heart Study, researchers found decreased fibrinolytic activity to be the main 
determinant of ischemic heart disease in younger men (18). 
 Individuals with OSA exhibit an altered hemostatic balance. Specifically, markers 
of coagulation are elevated and potential for fibrinolysis is decreased. Von Kanel et al. 
observed that plasminogen activator inhibitor 1 (PAI-1), which inhibits tissue plasminogen 
activator (tPA), the main stimulus of the fibrinolytic process, correlated with AHI and 




hypoxic conditions experience a greater PAI-1 gene expression with a concomitant increase 
in PAI-1 mRNA stability, resulting in greater lung fibrin deposition (23). It has also been 
observed that untreated OSA subjects have a shortened whole blood clotting time, 
suggesting that OSA is also accompanied with global hypercoagulability (12). Evidence 
also suggests that hypoxic conditions result in a shortened coagulation time with a 
concurrent rise in Factor VIII (5). 
 Many instances of myocardial infarction are preceded by physical exertion (11, 21). 
During exercise, both coagulation and fibrinolysis increase proportional to intensity (14). 
Acil et al. found that persons with coronary artery disease exhibit a hemostatic balance 
favoring greater coagulation after an acute bout of exercise (1). This could be 
mechanistically linked with exertion-related ischemic events as occlusive thrombi are 
responsible for a greater portion of exertion-related events than events triggered by other 
causes (11). Although hemostatic responses to exercise are clinically important, these 
responses are relatively unknown in obstructive sleep apnea patients. Rangemark et al. 
found that OSA subjects exhibited increases in PAI-1 activity with values remaining 
significantly elevated before and after 4 minutes of submaximal cycle ergometer exercise 
compared to matched controls (24). After exercise, tPA showed a four-fold increase but did 
not significantly differ between groups (24). However, this study did not analyze any factors 
of coagulation other than platelet activity, which did not significantly change (24). The aim 
of this study is to determine if obstructive sleep apnea impacts the Factor VIII, tPA and PAI-








 All subjects gave informed written consent on the study protocol approved by the 
James Madison University Institutional Review Board. OSA subjects were recruited from 
the JMU community and Sentara Rockingham Memorial Hospital (SRMH) Sleep Clinic. 
All SRMH subjects were diagnosed with sleep apnea and not currently using continuous 
positive airway pressure (CPAP) as treatment. Eighteen males (> 18 years of age) with 
observed sleep problems or significant snoring were recruited for the present study. 
Mobility issues, and/or evidence of cardiovascular, pulmonary, and metabolic diseases were 
criteria for exclusion in both OSA and Non-OSA groups. Demographic data is presented in 
Table 1 for OSA and Normal individuals.   
To establish likelihood of Sleep Apnea and screen for exclusion criteria in 
community-recruited participants, administration of established sleep surveys including 
Berlin Questionnaire, Epworth Sleepiness Scale, IPAQ, STOP Questionnaire, a Pre-
Screening form, and Medical/Health History were completed prior to participation. High 
risk for cardiovascular disease, per the American College of Sports Medicine (ACSM) 
guidelines (2), highly active lifestyles, and use of heart rate/blood pressure/ blood thinning 
medications were criteria for exclusion. Subjects were required to wear an ApneaLink 
(ResMed; San Diego, CA) device to measure sleep disturbances by thoracic measurements, 
oxygen saturation (SpO2), respiratory effort, and airflow during sleep hours. The Apnea-
Hypopnea Index (AHI) was used to determine the likelihood for OSA in these subjects. 
Apneas were defined as a complete cessation in respiration greater than or equal to 10 




concomitant reduction of oxygen saturation. An AHI  > 5 is the accepted criteria for 
diagnosed OSA (30). Subjects recruited at SRMH Sleep Clinic were evaluated for any 
known diseases and exclusions which were reported to the researcher by the on-site 
physician. All data was collected in the Human Performance Lab of James Madison 
University. All written, electronic data and subject information was stored in a locked file 
cabinet and password locked laptop in a locked file cabinet and room within the laboratory. 
Each participant entering the study completed the appropriate questionnaires and visited the 
laboratory three non-consecutive days over the span of approximately 7 – 10 days.  
 
Treadmill Test 
 Testing was done in the morning following an overnight fast. A resting blood draw 
was administered after 15 minutes of supine rest. Prior to testing, a warm up of 3 to 4 
minutes was performed, after which subjects performed two, five minute stages of exercise 
at 35% and 70% estimated VO2 reserve. During the test, walking speed and incline level 
were adjusted to obtain desired intensity, respectively. Metabolic variables were monitored 
continuously using a metabolic measurement system (Parvo Medics; Sandy, UT). Heart rate 
was determined continuously via a Polar® heart rate monitor. Immediately following 
exercise, a second blood draw was obtained within two minutes of completing the exercise 
test. 
 
Blood Sampling and Analysis 
   Blood draws were obtained from an antecubital vein after 15 minutes of supine rest 




heparin, sodium citrate, and acidified citrate. Blood collected in heparin vials was 
immediately analyzed for hematocrit using the micro-hematocrit method. Samples collected 
in sodium citrate and acidified citrate were spun for 20 minutes at 15000 rpm in a 
refrigerated centrifuge. Plasma was extracted from spun samples and stored at -80⁰ C until 
analysis. Blood analysis was performed by standardized Enzyme-Linked Immunosorbent 
Assay (ELISA) for Factor VIII activity, tPA antigen, tPA activity, and PAI-1 activity. Post 
exercise values for all of these variables were corrected for plasma volume changes, which 
were estimated using the method described by Van Beaumont et al. (33). 
 
Statistical Analysis 
Factor VIII, tPA antigen and activity, and PAI-1 activity were analyzed using Repeated 
Measures Analysis of Variance (ANOVA). Disease status (OSA vs. Non-OSA) was the 
between-subjects factor and exercise (Pre vs. Post) was the within-subject factor. Post hoc 
testing was done using paired and independent t-tests with a Bonferroni correction factor. 
Correlation analysis was performed between all hemostatic variables and age, BMI, and 
disease severity. A priori statistical significance was set at P < 0.05. TPA antigen and PAI-
1 activity were not normally distributed according to Shapiro-Wilk, so a log10 










 Eighteen subjects were recruited for the present study. Normal and OSA individuals 
were similar in age, height, weight, and BMI. The Apnea-Hypopnea Index was 
significantly higher (P < 0.05) in OSA (13.00 + 12.6) than controls (1.44 + 1.33) 
respectively indicating mild disease severity in OSA (30). Table 2 presents average VO2 
and heart rate values during exercise at 70% predicted VO2 reserve. Oxygen consumption 
reached similar levels (P > 0.05) between OSA individuals and controls (28.97 + 7.99 
ml/kg/min vs. 25.29 + 5.19, respectively). There were no differences (P > 0.05) in heart 
rates during exercise between controls (136.83 + 23.48 bpm) and OSA (128.83 + 19.35 
bpm).   
Figure 2 displays mean Factor VIII antigen responses to exercise. Factor VIII 
antigen significantly (P < 0.05) increased from pre to post exercise in controls (0.84 + 0.30 
IU • ml-1 to 1.13 + 0.42 IU • ml-1) and OSA (1.06 + 0.37 IU • ml-1 to 1.15 + 0.31 IU • ml-
1). There was no main effect for condition or an exercise x condition interaction.  
 Mean values for tPA antigen in response to exercise are displayed in Figure 3. Post 
exercise values were significantly (P < 0.05) increased in controls (1.18 + 0.81 ng • ml-1 to 
1.91 + 1.36 ng • ml-1) and OSA (1.74 + 1.89 ng • ml-1 to 2.87 + 2.87 ng • ml-1). There was 
no main effect for condition or an exercise x condition interaction.  
 Figure 4 displays mean tPA activity responses to exercise. There was no main effect 
for condition or an exercise x condition interaction. tPA activity significantly (P < 0.05) 
increased post exercise similarly in controls (0.08 + 0.06 IU • ml-1 to 0.78 + 0.35 IU • ml-




 Mean values for PAI-1 activity in response to exercise are displayed in Figure 5. A 
trend (P = 0.05) was observed for a main effect of OSA compared to controls (21.35 + 
10.65 U • ml-1 to 24.85 + 18.83 U • ml-1 vs. 8.70 + 9.11 U • ml-1 to 8.15 + 7.90 U • ml-1, 
respectively). There was no main effect for exercise; nor was there an exercise x condition 
interaction (P > 0.05).  
 Figure 6 displays the correlation between post exercise FVIII antigen and BMI. 
There was a significant positive correlation between post exercise FVIII antigen and BMI 
(R = .520; P < 0.05). Correlations for pre exercise tPA antigen are presented in Figures 7 
and 8. Pre exercise tPA antigen was significantly correlated with AHI (R = .489; P < 0.05) 
and age (R = .496; P < 0.05), respectively. No other hemostatic variables were significantly 

















 The primary finding of the present study is Obstructive Sleep Apnea (OSA) does 
not appear to have an effect on the hemostatic response to exercise compared to healthy 
individuals. However, OSA may have an effect on resting PAI-1 levels. 
 Under normal conditions, FVIII increases during exercise in direct proportion to 
exercise intensity (14, 6, 3, 37, 20). Because FVIII acts as a coenzyme in relatively small 
amounts along the coagulation cascade, an increase in concentration appears to have an 
exponential effect in coagulation potential making it a primary variable for study (6). 
Further, elevations in FVIII has been associated with increased risk for cardiovascular 
disease (CVD) making its evaluation of clinical importance (19, 27, 31). Our data show 
similar increases in FVIII antigen in both OSA and normal individuals after acute aerobic 
exercise. Currently, there are no known studies describing the coagulation potential after 
exercise in OSA. Bartsch et al. showed an increase in FVIII in fifteen army pilots after 
hypoxia exposure (5). However, the hypoxia exposure and subsequent oxygen desaturation 
levels may not be comparable to OSA. Although there appears to be no differences in the 
exercise response of FVIII, an increased coagulation potential may still occur among other 
factors along the coagulation cascade. Additionally, post exercise FVIII antigen was 
positively correlated with BMI, although there appeared to be no differences in BMI 
between groups. Activation of the sympathetic nervous system in larger individuals may 
account for this association (6). Indeed, BMI is a risk factor for OSA development (30). 
Further, if left untreated, OSA individuals have increased risk of cardiovascular disease 





 Recently, Obstructive Sleep Apnea appears to be accompanied with an altered 
hemostatic balance at rest (12, 34, 35). Guardiola et al. demonstrated shortened clotting 
times in OSA individuals (12) suggesting a pro coagulant imbalance. However, limited 
evidence exists for the hemostatic response to exercise in OSA. During exercise, 
fibrinolytic potential increases in parallel with coagulation potential (3, 26, 37, 7, 38, 20). 
Specifically, increases in tPA antigen and activity are readily observed (7, 38, 20), likely 
due to increased sympathetic nervous system activity (6). Our findings suggest that mild 
OSA has a similar tPA antigen and activity response to exercise as healthy individuals. 
Further, increases in tPA activity after exercise exists in OSA similar to normal subjects, 
confirming previous reports (24). Although there are no known studies evaluating tPA 
antigen and OSA, it appears that the exercise response is unaffected.  
Pre exercise tPA antigen levels were positively associated with OSA severity and 
age. Age and tPA antigen have been previously shown to be correlated (28), however the 
relationship in OSA is less described. The data suggest OSA severity positively impacts 
tPA antigen.  Elevations in tPA antigen have been indicated to increase risk of 
cardiovascular disease and acute cardiovascular events (31). Although, individuals in the 
present study were classified as having mild disease severity (> 5 - < 15 AHI) (30), we 
speculate that this association may contribute to the observed elevated CVD risk at 
increasing disease severity (16). The current findings are novel in describing the 
relationship of tPA antigen and OSA.  
Perhaps the greatest impact on hemostasis in OSA is due to PAI-1 (34, 35, 41). Von 
Kanel et al. found elevated PAI-1 levels in OSA (34) with others confirming similar 




are similar to that of Rangemark et al. (24) showing elevated PAI-1 activity levels in OSA, 
unaffected by exercise. Together, mild OSA appears to have an independent effect on PAI-
1 activity levels potentially lowering fibrinolytic capacity. Acute exercise has been 
suggested to temporarily lower PAI-1 in clinical populations thus enhancing chronically 
diminished fibrinolytic potential (39, 15). However, this does not appear to occur in low-
moderate intensity exercise in mild OSA. Possible mechanisms may exist that explain the 
differences in PAI-1 activity. Pinsky et al. found elevated PAI-1 mRNA in mice 
accompanied with greater PAI-1 mRNA stability after sustained exposure to hypoxia (23). 
Indeed, Obstructive Sleep Apnea exhibits several short duration episodes of hypoxia during 
supine rest (30), however these mechanistic avenues should be further explored. Contrary 
to previous findings, there was no observed correlation between PAI-1 activity and AHI 
(34). OSA individuals in the present study were classified as mild disease severity, which 
may account for the unobserved relationship. Therefore moderate (AHI 15 - < 30) or severe 
(AHI > 30) individuals may need to be examined to clarify this association. It is possible, 
that greater disease severity accompanied with greater hypoxia exposure, produces this 
observed association.          
 Altered hemostatic balance has been associated with increased risk in developing 
cardiovascular disease (13, 9, 18, 31, 32). Specifically, FVIII appears to be elevated in 
CVD and is now regarded as a possible risk factor (27, 32). Rumley et al. found increases 
in relative odds of ischemic heart disease with increasing concentrations of Factor VIII 
(27). Previous studies have shown similar associations (9). Further, impaired fibrinolytic 
activity is also associated with increased risk (18). Therefore, the hemostatic variables 




Additionally, many cardiovascular events seem to occur after a period of physical 
exertion (21, 11). These events are due mostly to occlusive thrombus formation (3, 20). 
Because individuals with OSA already exhibit a hemostatic imbalance (34, 35), the 
exercise response is of clinical importance. It appears that mild OSA does not influence 
the hemostatic response to low-intensity exercise. However, it is possible fibrinolytic 
potential may become compromised either during higher intensity activity (11) or 
increasing disease severity (35).  
Several limitations exist that may have impacted our findings. Firstly, exercise 
intensities were selected based on predictions of VO2 reserve with BMI and self-reported 
activity levels (data not shown). Because maximal aerobic capacity was not determined, 
variation in predictions could have influenced the current findings. Factor VIII increases 
directly proportional to exercise intensity with greater levels achieved during vigorous 
exercise (3, 38) while fibrinolytic potential increases even at modest intensity (26). 
However, because responses were observed in both groups, the exercise stimulus might 
have been sufficient for appropriate comparisons. Additionally, the prescribed exercise was 
similar to previous reports, further supporting the current findings (24). Obstructive Sleep 
Apnea appeared to have no impact on coagulation potential after exercise. Although FVIII 
is unaffected, other factors along the coagulation cascade could be influenced. Robinson et 
al. showed no differences in FVIII levels in OSA individuals compared to normal controls 
while increases in resting levels of factors XII, VII, and Thrombin anti-thrombin complex 
were evident (25). Therefore, future studies will need to evaluate other potential candidates. 
The current sample size may also be insufficient, therefore increases in sample size and 




In conclusion, the hemostatic response after acute exercise is well established. 
However evidence of this response in Obstructive Sleep Apnea is limited. Primarily, the 
hemostatic changes from acute aerobic exercise are not affected in mild OSA. Rather, PAI-
1 activity seems to be elevated which remains after exercise showing greater influence of 
OSA on fibrinolytic than coagulation potential. Additionally, it appears disease severity, 
BMI, and age have some influence on select hemostatic factors in mild OSA individuals. 
Currently, the present study adds to the limited data of hemostatic changes and the first to 
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Figure 1. Overview of Coagulation Cascade 
 
Figure 2. Mean (+ SE) Factor VIII antigen (IU • ml-1) pre exercise and post exercise for 
OSA (circles) and controls (squares). * Main effect for exercise (Post > Pre). 
 
Figure 3. Mean (+ SE) tPA antigen (ng • ml-1) pre exercise and post exercise for OSA 
(circles) and controls (squares). * Main effect for exercise (Post > Pre).  
 
Figure 4. Mean (+ SE) tPA activity (IU • ml-1) pre exercise and post exercise for OSA 
(circles) and controls (squares). * Main effect for exercise (Post > Pre).  
 
Figure 5. Mean (+ SE) PAI-1 activity (AU • ml-1) pre exercise and post exercise for OSA 
(circles) and controls (squares). † Main effect for OSA (P = 0.05). 
 
Figure 6. Post Exercise Factor VIII antigen (IU • ml-1) and BMI (kg/m2). *Significant 
correlation (P < 0.05). 
 
Figure 7. Pre Exercise tPA antigen (ng • ml-1) and AHI. *Significant correlation (P < 0.05). 
 







 OSA Controls 
Age (yrs) 45 + 13 38 + 12 
Height (cm) 177.87 + 7.18 179.64 + 4.70 
Weight (kg) 92.75 + 14.39 88.20 + 10.1 
BMI (kg/m2) 29.35 + 3.73 27.39 + 3.24 
AHI 13.00 + 12.6* 1.44 + 1.33 







 VO2 (ml/kg/min) Heart Rate (bpm) 
OSA  25.29 + 5.19 128.83 + 19.35 
Controls  28.97 + 7.99 136.83 + 23.48 































































































































































































































































James Madison University 
Department of Kinesiology 
Informed Consent 
Purpose 
You are being asked to volunteer for a research project conducted by Dr. Trent Hargens 
from James Madison University entitled, “The effects of obstructive SLEEP apnea on 
AUTONOMIC and cardiovascular FUNCTION during steady-state EXERCISE”, or 
the SAFE study. 
The primary goal of this study is to examine whether individuals who are newly 
identified as high risk for, or diagnosed with, obstructive sleep apnea (OSA) show altered 
heart rate and cardiovascular variables during sub-maximal exercise.  This may provide a 
clearer picture into why OSA increases the risk for other chronic health problems. 
Experimental Procedures 
You will be asked to visit the Human Performance Laboratory (HPL) in Godwin Hall 3 
times over the course of about 7 – 10 days.  Your total time commitment for participation 
in this study will be approximately 2 and a half hours.  In addition, you will be asked to 
wear (for one night) an at-home sleep testing device (the ApneaLink) to screen you for 
possible OSA.  It is equipped with straps, a finger probe, and a nasal cannula. It measures 
your breathing activity, heart rate, and blood oxygen levels, and is harmless to wear.   If 
you have previously been diagnosed with OSA through Sentara RMH, then you will not 
have to wear the ApneaLink device.  Also, you will be asked to wear a device (an 




day, while wearing the same device on your wrist at night while you sleep.  Detailed 
information on each visit is provided below: 
Visit 1 
Before any test is given, you will be asked to complete a screening form and an informed 
consent, to insure that you meet the study criteria, that you do not have any factors that 
would disqualify you from participation.  Upon completion of the informed consent, you 
will be asked to complete a short health history questionnaire providing information 
about your characteristics and health.  You will then be asked complete 3 standardized 
questionnaires about snoring, the quality of your sleep, daytime sleepiness, and risk for 
OSA. 
You will then have your height, weight, waist circumference and neck circumference 
measured.  After that, your body composition will be analyzed via a Dual-energy x-ray 
absorptiometer (DEXA).  The DEXA scan will allow us to measure your percent body fat 
and the mineral content and density of your bones.  The DEXA is much like an X-ray 
machine.  The DEXA will scan your entire body very slowly; so, you will need to lie on a 
table without moving for almost 10 minutes, while the DEXA is passed over your entire 
body.  You will feel no discomfort associated with this test. 
At the end of this first visit you will also be instructed on the proper use procedures for 
wearing the ApneaLink device for your one-night sleep assessment, as well as 
instructions on wearing the accelerometer.  An accelerometer is a small device that is to 




Following the DEXA scan, we will ask that you wear a heart rate monitor while lying 
down in a darkened room for 15 minutes to get measures of your heart rate.  We will also 
obtain your resting blood pressure. 
Visit 2 
The following day after Visit 1, you will be asked to return to the HPL to return the 
ApneaLink device.  Following this, we will ask that you wear a heart rate monitor while 
lying down in a darkened room for 15 minutes to get measures of your heart rate.  We 
will also obtain your resting blood pressure.  This visit should take about 30 minutes. 
Visit 3 
Approximately 5 – 6 days later, you will be asked to return to the HPL for your final 
visit.  For this visit you will undergo a submaximal treadmill exercise test.  You will be 
asked to walk on the treadmill for a total of about 15 minutes, which includes a 3 – 4 
minute warm-up, and 2 – 3 minute cool-down.  In between the warm-up and cool-down 
you will be asked to walk at 2 separate workloads, 1 fairly easy and 1 somewhat hard, for 
5 minutes at each workload.  During this test we will monitor the electrical output of your 
heart by placing electrodes directly on your skin across your chest, stomach and back. 
During the test, we will measure the electrical activity of your heart, your heart rate, 
blood pressure, your effort, and how much oxygen your body is using.  To see how much 
oxygen you use, we will ask you to breathe into a rubber mouthpiece.  During the test, 
you will breathe only through the mouthpiece and may experience some dryness in your 
mouth.  Prior to your arrival to the HPL for this visit, you will be asked to consume a 
normal meal (breakfast or lunch) and not to come to the HPL with a full stomach.  




blood (about 2 teaspoons) prior to and immediately after the exercise trial in order to 
determine the potential of your blood to coagulate.  These blood samples will be obtained 
from an arm vein. 
Follow-up testing 
If you are shown to have OSA, and you undergo treatment for OSA through continuous 
positive airway pressure treatment (CPAP), you will be asked to undergo repeat testing of 
all previously described tests (except for the ApneaLink device) after 6 months of 
treatment.  If you are shown to not have OSA, follow-up testing will not be done.   
Risks 
There are no risks associated with wearing an accelerometer.  Also, there is no risk 
associated with heart rate, blood pressure, height, weight, and waist and neck 
circumference measures.  You will not be asked to change any of your personal habits 
during the course of the study. Measurements with associated risks include:  the DEXA 
scan and treadmill exercise test.   
The amount of radiation that you will receive in the DEXA exam is less than the amount 
you will receive during a transatlantic flight, and is equal to about 1/20 of a chest x-ray.  
You should not be pregnant for this study because of risks from the DEXA scan radiation 
to the embryo or fetus.  If you feel that you might be pregnant, inform the research staff 
immediately. 
There is a risk of abnormal changes during the submaximal treadmill exercise test.  These 
changes may include abnormal blood pressure, fainting, heart rhythm disorders, stroke, 
heart attack, and death.  The chance of serious heart problems during maximal exercise 




exercise trial for this proposed study is sub-maximal vs. maximal, so the risk for 
complications is even less.  Every effort will be made to minimize risks of an abnormal 
response by reviewing you health history and providing adequate supervision of the 
exercise test.  All staff are certified by the American Heart Association in BLS (Basic 
Life Support). 
With the blood draw, there is the risk of discomfort, bruising, and, in rare instances, 
infection, lightheadedness, and fainting. We will use sterile procedures and trained 
personnel to minimize discomfort and complications. 
Benefits 
Participation may include knowledge about your health status.  You will receive 
information on your body composition, including percent body fat and bone mineral 
density, an assessment of your sleep quality and risk for sleep apnea, an assessment of 
your physical activity level, and cardiovascular fitness.  In addition, a $50 stipend is 
provided for subjects who complete the study protocol.  Indirect benefits of participating 
in this study will be helping the researchers better understand the relationship between 
sleep apnea and cardiovascular disease risk. 
Inquiries 
If you have any questions or concerns or you would like to receive a copy of the final 
aggregate results of this study, please contact Dr. Trent Hargens at hargenta@jmu.edu or 
(540) 568-5844.  
Questions about Your Rights as a Research Subject 
Dr. David Cockley     Dr. Stewart Pollock 




James Madison University    Sentara RMH Medical Center 
(540) 568-2834      (540) 689-1000 
cocklede@jmu.edu     SGPOLLO3@SENTARA.com 
Confidentiality 
All data and results will be kept confidential. You will be assigned an identification code. 
At no time will your name be identified with your individual data. The researcher retains 
the right to use and publish non-identifiable data. All data will be kept secured in a 
locked cabinet. All electronic data will be kept on a password-protected computer.  Final 
aggregate results will be made available to participants upon request. 
Freedom of Consent 
Your participation is entirely voluntary.  You are free to choose not to participate.  
Should you choose to participate, you can withdraw at any time without consequences of 
any kind. 
I have read this consent form and I understand what is being requested of me as a 
participant in this study.  I freely consent to participate.  I have been given satisfactory 
answers to my questions.  The investigator provided me with a copy of this form.  I 
certify that I am at least 18 years of age. 
________________________________ __________________________________ 
Name of Subject (Printed)   Name of Researcher (Printed) 
________________________________ __________________________________ 
Name of Subject (Signed)   Name of Researcher (Signed) 
________________________________ __________________________________ 




Medical and Health History Form  
Name:      Date of Birth: ________________ 
Ethnicity:    
Height:     ft Weight:     pounds 
Gender:  Female   Male   
Campus Address:             
Campus Telephone Number: ____________________ Campus Email Address: 
_____________________ 
Address for Permanent Residence:  
________________________________________________________ 
Person to contact in case of emergency:  
_____________________________________________________ 
Relationship:  _____________    Daytime Telephone: ____________ Home 
Telephone:     
Primary Care Physician:   ________________________          Telephone:   
   
Medical History 
Please indicate any current or previous conditions or problems you have experienced or 
have been told by a physician you have had:  
  Yes     No 
Heart disease or any heart problems:   _____   _____ 
Rheumatic fever:     _____   _____ 




Circulation problems:     _____   _____ 
Kidney disease or problems:    _____   _____ 
Urinary problems:     _____   _____ 
Reproductive problems:    _____   _____ 
Musculoskeletal problems:    _____   _____ 
Fainting or dizziness, especially with exertion: _____   _____ 
Neurological problems/disorders:   _____   _____ 
High blood pressure:     _____   _____ 
Low blood pressure:     _____   _____ 
High blood cholesterol:     _____   _____ 
Diabetes:      _____   _____ 
Thyroid problems:     _____   _____ 
Eating disorders (bulimia, anorexia):   _____   _____  
Allergies:      _____   _____ 
If "yes" to any of the above please indicate the date, explain, and describe: 
            
            
             
Please list any hospitalizations/operations/recent illnesses (Type/Date):   
      
      





Do you ever feel faint, short of breath, or chest discomfort with exertion? Yes: ________    
No: ________ 
If "yes", please explain :         
          
  
     
Are there any orthopedic limitations you have that may restrict your ability to perform 
hard running exercise or intense strength-type exercises?  (back, hips, knees, ankles)    
Yes                        No  _____ 
If  "yes" please explain:       
      
      
     
Family Health History 
Has anyone in your family (blood relatives only) been diagnosed or treated for any of the 
following? 
   Yes  No    Relationship   Age 
Heart attack _____  _____      _____ 
Heart disease _____  _____      _____ 
High blood pressure _____  _____      _____ 
Stroke _____  _____      _____ 
Kidney disease _____  _____      _____ 





Do you add salt to your food?  Yes  ___   No  ___   Are you on any special type of diet?  
Yes  ___   No ___ 
If "yes" please describe         
            
  
Do you drink caffeinated beverages?  Yes  _____   No ______     How many cups per day?                     
  
Do you drink alcoholic beverages?     Yes  _____     No  ______  How many drinks per 
week? _________ 
What is the average number of drinks that you consume on the weekend? _________ 
Did you use tobacco products in the past (more than 12 months ago)? Yes ______     No 
_______ 
Sleep Habits Evaluation 
Do you have episodes of parasomnias (disorders such as sleep walking, sleep talking, night 
terrors, body rocking, bedwetting that will cause partial or full awakening?)   Yes            
No  
Do you show signs of sleep disturbances (such as insomnia, daytime sleepiness) when you 
are anxious, stressed?  Yes     No   
Do you have difficulties to fall asleep if a certain object or a certain situation is absent such 
as listening to the radio, watching the television, etc?  Yes    No   
Do you have difficulties to fall asleep earlier or later of your usual bedtime? Yes    




Do you wake up at night to get a little snack? Yes   No   
If “yes”, do you think that the snack is helping you to go back to sleep? Yes   No 
  
Do you have hallucinations (vivid images that look like dreams occurring when you sleep) 
or find yourself physically weak or paralyzed for a few seconds?                Yes            
No   
Tonsils and Adenoids evaluation questionnaire 
Do you have a history of recurrent tonsillitis which is an inflammation of the tonsils 
(clusters of tissue that lie in bands on both sides of the back of the throat) caused by an 
infection? In tonsillitis, the tonsils are enlarged, red, and often coated either partly or 
entirely?  Yes    No   
Did you ever have inflammation of the adenoids (single clump of tissue in the back of the 
nose) causing a   blockage of the back of the nose, chronic and recurrent fluid or 
infections of your ears, or chronic or recurrent sinus infections?                                 Yes
   No   
Did you have tonsillectomy (tonsils removed) or adenoidectomy (adenoids removed)? Yes
   No  
Medications 
Please list all medications (prescription and over-the-counter) you are currently taking or 
have taken in the past week:          
            
    ______       










Please sign to indicate the above information is correct: 
 ____         
   Print Name       Signature                                    Date 
 
 
Follow Up Review and Interview by:                   
____________________________________ 













Subject Prescreening Information 
 




Average Exercise Habits over the Past 2 Months: 
Avg. # days of exercise per week: 
Avg. # of days of aerobic exercise per week: 
Avg. # of days of resistance exercise per week: 
Do you currently use medications of any kind? 
Have you previously been diagnosed with a heart or lung disease? 
Do you have diabetes? 
Have you previously been diagnosed with Obstructive Sleep Apnea? 
If yes, are you currently being treated for it? 
Snoring 
Do you snore? 
If yes, do you snore:  (circle one) 
1 Day per week 
2-4 Days per week 






















Age _______ Age pred. max HR ________ 85% APMHR ________ 
 
35% of Predicted VO2 Reserve________________ 70% of Predicted 
VO2Reserve______________ 
 
Ht (in) ______ Wt (kg) ______ (lbs) _______ Resting HR ___________(seated) 
___________ (standing) 
 









Warm-up       
1 
2.0 / 0%     
Warm-up       
2 
2.0 / 0%     
Stage 1           
1 
/     
2 /  *   
3 /     
4 /  *   
5 /     
Stage 2           
6 
/     
7 /  *   
8 /     
9 /  *   
10 /     
Recovery      
1 2.0 / 0%     
2      
3      
4      




VO2 Stage 1: ________ mL/kg/min  VO2 Stage 2: _________ mL/kg/min 
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